![Kentaro Yoshimatsu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kentaro Yoshimatsu
Fundador en Rin Institute, Inc. .
Perfil
Kentaro Yoshimatsu is the founder and President & Representative Director of Rin Institute, Inc. which is founded in 2016.
He is currently a Director at Anaeropharma Science, Inc. Dr. Yoshimatsu was the Chief Scientific Officer & Senior Vice President at Eisai Co., Ltd.
from 1978 to 2011.
He was also the President of H3 Biomedicine, Inc. Dr. Yoshimatsu received his undergraduate, graduate, and doctorate degrees from the University of Tokyo.
Cargos activos de Kentaro Yoshimatsu
Empresas | Cargo | Inicio |
---|---|---|
Anaeropharma Science, Inc.
![]() Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Director/Miembro de la Junta | - |
Rin Institute, Inc.
![]() Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Fundador | 21/01/2016 |
Antiguos cargos conocidos de Kentaro Yoshimatsu.
Empresas | Cargo | Fin |
---|---|---|
EISAI CO., LTD. | Director Técnico/Científico/I+D | 30/09/2011 |
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Presidente | - |
Formación de Kentaro Yoshimatsu.
University of Tokyo | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
EISAI CO., LTD. | Health Technology |
Empresas privadas | 3 |
---|---|
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Anaeropharma Science, Inc.
![]() Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Rin Institute, Inc.
![]() Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Health Technology |
- Bolsa de valores
- Insiders
- Kentaro Yoshimatsu